自20世纪中叶发现第一个喹诺酮类抗菌药萘啶酸以来,目前该类药物已发展至第四代,以氟喹诺酮类为代表,表现出更强的抗菌作用和更广的抗菌谱,其市场占有率仅次于β-内酰胺类抗菌药物。但随着该类药物临床广泛使用,耐药问题频现,同时也发现部分氟喹诺酮类药物具有心脏毒性、肝脏毒性和光毒性等不良反应,致其应用受限。发展新型喹诺酮结构以克服氟喹诺酮类药物缺点为临床所 Since the first quinolone antibacterial nalidixic acid was discovered in the middle of the 20th century, at present, such drugs have been developed to the fourth generation, represented by fluoroquinolones, showing stronger antibacterial activity and broader antibacterial spectrum, which Market share second only to β-lactam antibiotics. However, with the widespread use of such drugs in clinical practice, drug-resistant problems are frequent, and some fluoroquinolones have also been found to have adverse effects such as cardiotoxicity, hepatic toxicity and phototoxicity, and their application is limited. The development of new quinolone structure to overcome the shortcomings of fluoroquinolones clinically